ArticleJAMA otolaryngology-- head & neck surgery2025
Biochemical Profile of and Factors Associated With Recurrence in Primary Hyperparathyroidism.
Article in JAMA otolaryngology-- head & neck surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Using biochemical profiles of patients with primary hyperparathyroidism allows surgeons to preoperatively identify patients who are more likely to have single-gland disease (SGD) vs multigland disease (MGD). Additionally, biochemical profiles may be used to monitor patients who are at increased risk for recalcitrant disease. Objective: To assess the associations of preoperative imaging localization, intraoperative parathyroid hormone (PTH) kinetics, and surgical pathology (SGD vs MGD) relative to baseline intact serum PTH, as well as establish independent risk factors for recalcitrant hyperparathyroidism. Design, Setting, and Participants: This retrospective cohort study used data from a rural tertiary care center treating adult patients who underwent elective parathyroidectomy for primary hyperparathyroidism between November 1, 2006, and January 30, 2023. Main Outcomes and Measures: Baseline serum biochemical profiles were used to stratify patients into 2 cohorts: low PTH (<100 pg/mL) and high PTH (≥100 pg/mL). Preoperative imaging results, surgical pathology results, intraoperative PTH kinetics, and long-term outcomes were compared between the 2 groups. Long-term follow-up revealed parameters of patients with biochemical recurrence. Results: Of 1202 patients in the study, 536 were included in the low-PTH cohort (mean [SD] age at diagnosis, 61.7 [12.7] years; 430 [80.2%] female) and 666 in the high-PTH cohort (mean [SD] age at diagnosis, 61.9 [13.6] years; 501 [75.2%] female), with a median (IQR) follow-up of 4.8 (8.8) years. Preoperative imaging localized more readily in the high-PTH cohort (559 patients [90.8%] vs 441 patients [83.4%]; odds ratio [OR], 1.94; 95% CI, 1.30-2.90). SGD was more likely among patients in the high-PTH group (594 [89.2%] vs 455 [84.9%]; OR, 1.47; 95% CI, 1.05-2.06). Patients with high baseline PTH tended to have more optimal intraoperative PTH kinetics than those with low baseline PTH (intraoperative PTH decline, 70.1% vs 63.6%; difference, 6.5 percentage points; 95% CI, 1.5-11.2 percentage points). Postoperatively, a calcium level of 10.0 mg/dL at 6 months was associated with recurrence (OR, 6.96; 95% CI, 3.24-14.94). Conclusions and Relevance: In this cohort study, high baseline PTH levels were associated with improved preoperative image localization and presence of SGD. Furthermore, intraoperative PTH kinetics were more optimal in patients with high baseline PTH levels. Targeted surgical approaches must be considered carefully in patients with low baseline PTH levels. Patients with postoperative calcium of 10 mg/dL at 6 months should warrant consideration of close follow-up, as these patients are more likely to have recalcitrant disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.